NEW YORK, July 12, 2024 /PRNewswire/ -- The global central nervous system (CNS) stimulant drugs market size is estimated to grow by USD 6.48 billion from 2023-2027, according to Technavio. The market ...

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, affecting 12%–13% of adolescents in the United States, according to some studies.

Annual prescriptions for drugs to treat attention-deficit/hyperactivity disorder (ADHD) increased 157% in Ontario from 2015 to 2023, according to a new study from ...

The Center for Drug Safety and Effectiveness at Johns Hopkins University has led a study into prescription drug use of multiple concurrent central nervous system (CNS)-active drugs. They found ...

The number of adults in Ontario who started taking stimulants, mainly to treat ADHD, more than doubled in the wake of the ...

The FDA is updating warnings for stimulants prescribed for attention-deficit/hyperactivity disorder (ADHD) and other conditions, citing concerns about nonmedical use ...

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite's product lines consist of immediate-release and controlled ...

The combination of prescribed central nervous system stimulants, such as drugs that relieve ADHD symptoms, with prescribed opioid medications is associated with a pattern of escalating opioid intake, ...